NO931745L - STABILIZED, STRONG EFFECTIVE GRF ANALOGS - Google Patents

STABILIZED, STRONG EFFECTIVE GRF ANALOGS

Info

Publication number
NO931745L
NO931745L NO93931745A NO931745A NO931745L NO 931745 L NO931745 L NO 931745L NO 93931745 A NO93931745 A NO 93931745A NO 931745 A NO931745 A NO 931745A NO 931745 L NO931745 L NO 931745L
Authority
NO
Norway
Prior art keywords
stabilized
val
amino acid
grf analogs
strong effective
Prior art date
Application number
NO93931745A
Other languages
Norwegian (no)
Other versions
NO931745D0 (en
Inventor
Alan R Friedman
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of NO931745L publication Critical patent/NO931745L/en
Publication of NO931745D0 publication Critical patent/NO931745D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Tires In General (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)
  • General Preparation And Processing Of Foods (AREA)

Abstract

GRF-peptid med Val eller Ile i stedet for aminosyreresten som normalt finnes i 19-stilling, med Gly, Thr, Val eller Ile i stedet for amino- syreresten som normalt finnes i 2-stilling, og med en aminosyre valgt fra gruppen bestående av Ala, Val, Leu, Ile eller Gly i 15-stilling. Peptidene har forøkt stabilitet i plasma og vandige miljøer ved nøytral pH.GRF peptide with Val or Ile instead of the amino acid residue normally found in the 19 position, with Gly, Thr, Val or Ile instead of the amino acid residue normally found in 2 position, and with an amino acid selected from the group consisting of Ala, Val, Leu, Ile or Gly in 15 position. The peptides have increased plasma stability and aqueous environments at neutral pH.

NO931745A 1990-11-14 1993-05-13 STABILIZED, STRONG EFFECTIVE GRF ANALOGS NO931745D0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61417090A 1990-11-14 1990-11-14
PCT/US1991/008248 WO1992008481A1 (en) 1990-11-14 1991-11-13 Stabilized, potent grf analogs

Publications (2)

Publication Number Publication Date
NO931745L true NO931745L (en) 1993-05-13
NO931745D0 NO931745D0 (en) 1993-05-13

Family

ID=24460133

Family Applications (1)

Application Number Title Priority Date Filing Date
NO931745A NO931745D0 (en) 1990-11-14 1993-05-13 STABILIZED, STRONG EFFECTIVE GRF ANALOGS

Country Status (11)

Country Link
EP (1) EP0565536A1 (en)
JP (1) JPH06502650A (en)
AU (1) AU655791B2 (en)
CA (1) CA2092906A1 (en)
CZ (1) CZ85393A3 (en)
FI (1) FI932185A0 (en)
HU (1) HUT63857A (en)
NO (1) NO931745D0 (en)
RU (1) RU2119800C1 (en)
SK (1) SK49093A3 (en)
WO (1) WO1992008481A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9906715D0 (en) * 1999-03-23 1999-05-19 Ferring Bv Compositions for promoting growth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
ATE113965T1 (en) * 1989-06-16 1994-11-15 Upjohn Co STABILIZED, STRONG GRF ANALOGUES.

Also Published As

Publication number Publication date
RU2119800C1 (en) 1998-10-10
SK49093A3 (en) 1993-10-06
NO931745D0 (en) 1993-05-13
HUT63857A (en) 1993-10-28
CZ85393A3 (en) 1994-03-16
CA2092906A1 (en) 1992-05-15
FI932185A (en) 1993-05-13
EP0565536A1 (en) 1993-10-20
AU9055191A (en) 1992-06-11
WO1992008481A1 (en) 1992-05-29
FI932185A0 (en) 1993-05-13
AU655791B2 (en) 1995-01-12
HU9301385D0 (en) 1993-09-28
JPH06502650A (en) 1994-03-24

Similar Documents

Publication Publication Date Title
AU9315398A (en) Chemokine peptides, variants, derivatives and analogs. their use in methods to inhibit or augment an inflammatory response
EP0333356A3 (en) Hirudin peptides
TW343198B (en) Cyclopeptides useful as adhesion inhibitors, process for the preparation thereof, and pharmaceutical composition containing them
KR850007801A (en) Method of producing polypeptide
HUP0003592A2 (en) Lh-rh peptide analogues, their use and pharmaceutical compositions containing them
UA35636C2 (en) Polypeptide possessing lung surfactant activity and pharmaceutical composition for treating respiratory distress syndrome in mammals
ATE368053T1 (en) ANTIMICROBIAL PEPTIDES
DK0479912T3 (en) Method for inhibiting the course of N-end rule in living cells
WO1995003327A3 (en) Peptides for neutralizing the toxicity of lipid a
EP0334244A3 (en) Bradykinin antagonist peptides
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
NO960939L (en) kininogenase inhibitor
DK0896615T3 (en) Soluble Peptide of Acetylcholinesterase Active as Calcium Channel Modulator
BR9306272A (en) Peptide and pharmaceutical composition
ATE63126T1 (en) TETRA- AND PENTA-PEPTIDES WITH THE SEQUENCE LYSYLARGINYL-ASPARTYL, AND THEIR USE AS ANTITROMBOTICS.
EP1006126A3 (en) Osteogenic peptides
ES2095255T3 (en) ANALOGS OF SUBSTITUTION OF PEPTIDES MAGAININA.
EP0161007A3 (en) Retro - inverso c-terminal hexapeptide analogues of substance p
NO931745L (en) STABILIZED, STRONG EFFECTIVE GRF ANALOGS
GB1533077A (en) 4-substituted enkephalin derivatives
EP0258203A3 (en) Novel substrate peptides
EP0312157A3 (en) Tetrapeptide renin inhibitors having a novel c-terminal amino acid
DE3782880D1 (en) INHIBITIVE PEPTIDES.
EA199900551A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING INHIBITOR IMMUNOGLOBULIN-RECEPTOR INTERACTION INHIBITOR
NO901558D0 (en) VASOACTIVE PEPTIDES.